ClinicalTrials.gg
RecruitingNCT07113665Updated Nov 19, 2026

Magnetic Resonance-Guided Focused Ultrasound Bilateral Capsulotomy for Refractory Anorexia Nervosa With Comorbid Obsessive Compulsive Disorder or Major Depressive Disorder

A Phase 1 interventional study of ExAblate Neuro 4000 in Anorexia Nervosa (DSM-IV Revised Criteria), sponsored by Sunnybrook Health Sciences Centre. Recruiting at 1 site in Canada. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-11-19.

Sponsored by Sunnybrook Health Sciences Centre · Phase 1, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Sep 2025; still recruiting 1 year 2 months later.
Updated Nov 19, 2026Start date movedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
10
Allocation
Not applicable
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 21 studies in Anorexia Nervosa with a site in Canada — 7 open to participants now, 8 under way, none of them phase 3. Anorexia Nervosa · Canada.

Planned enrollment
17th of 19
10 · median 51
Started
2025
the only one that year
Phase 1
3 of 21
1 open now
Registered
20th of 21
by date

Among the 21 studies in Anorexia Nervosa with a site in Canada, this one is the 17th largest by planned enrollment of the 19 interventional ones that give a count, is the only one that started in 2025, is one of 3 in phase 1, and was the 20th registered.

Anorexia Nervosa

471 studies on the registry are indexed under Anorexia Nervosa; 127 are open to participants now.

Browse Anorexia Nervosa studies →

Open to participants now

7 of the 21 studies in Anorexia Nervosa with a site in Canada are open now. Recruiting first, the newest first:

1 more — sign in →

All 7 open studies →

A study can be open while its sites in Canada have not opened yet or have stopped. Only those recruiting at a site in Canada →

Who these studies take

Of the 82 Anorexia Nervosa studies recruiting now, 18 (22%) set no upper age limit and 60 (73%) stop at 75 or younger; 48 take children under 18; 26 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 21 studies in Anorexia Nervosa with a site in Canada, or all of them as a file.
02

Study summary

The goal of this clinical trial is to evaluate the safety and initial clinical effectiveness of MRI-guided focused ultrasound (MRgFUS) thermal ablation (capsulotomy) in patients with treatment-refractory anorexia nervosa (AN) and comorbid obsessive-compulsive disorder (OCD) and major depressive disorder (MDD). The main questions it aims to answer are:

  1. Can MR-guided focused ultrasound capsulotomy be safely delivered through an intact skull in patients with treatment-refractory anorexia nervosa and comorbid OCD and/or MDD, with a safety and side-effect profile comparable to traditional radiofrequency neurosurgical approaches?
  2. Does MRgFUS capsulotomy produce clinical outcomes comparable to open surgical ablative procedures-specifically, improvements in anxiety, mood, quality of life, anorexia nervosa psychopathology, habit formation, and weight-in patients with treatment-refractory anorexia nervosa?

Participants will:

  1. Undergo baseline imaging and clinical assessments
  2. Receive a single MRgFUS capsulotomy targeting the ALIC
  3. Be monitored for 24 months post-treatment to assess adverse events, quality of life, and symptom changes using standardized clinical and neuropsychiatric measures
Read the detailed description

This is a single-centre, prospective, single-arm, non-randomized Phase I study evaluating the safety, feasibility, and preliminary clinical benefit of MRI-guided focused ultrasound (MRgFUS) for the treatment of treatment-refractory anorexia nervosa (AN) with comorbid obsessive-compulsive disorder (OCD) and/or major depressive disorder (MDD).

A total of 10 patients will be enrolled and treated with a single MRgFUS capsulotomy targeting the anterior limb of the internal capsule (ALIC).

Participants will undergo comprehensive pre-treatment evaluations, including psychiatric assessment, physical and nutritional status review, MRI imaging, and surgical eligibility screening. The treatment will be performed using the ExAblate 4000 system under continuous MRI guidance and real-time thermometry.

Participants will be followed at regular intervals, including immediately post-treatment and at 1, 3, 6, 12, 18, and 24 months post-procedure, to evaluate safety and changes in clinical symptoms.

03

Conditions studied

  • Anorexia Nervosa (DSM-IV Revised Criteria)

Keywords

  • Anorexia Nervosa
  • MR-guided Focused Ultrasound
  • bilateral capsulotomy
  • Obsessive Compulsive Disorder
  • Major Depressive Disorder
04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Men and women ≥18 and ≤65 years of age, inclusive.
  2. Patients who are competent and willing to give consent and able to attend study visits, as determined by both study Psychiatrist and the surgeon.
  3. diagnosis of Anorexia Nervosa, with co-morbid diagnosis of OCD and/or Major depressive disorder.
  4. Treatment refractoriness indicated by any of:

    1. Duration of illness more than 10 years with no more than three months of remission in terms of weight;
    2. At least three attempts at expert hospital based treatment that were not successful or where there was no sustained response to treatment;
    3. A pattern of increased medical instability requiring at least two episodes of emergency/involuntary re-feeding and lasting at least two years;
  5. Ability to provide /competent to make medical decisions.

Exclusion criteria

Exclusion Criteria:

  1. Patients with unstable cardiac status [e.g. Unstable angina pectoris on medication, Patients with documented myocardial infarction within six months, Congestive heart failure requiring medication (other than diuretic), Patients on anti-arrhythmic drugs, Severe hypertension (diastolic BP > 100 on medication)]
  2. Patients with standard for MR imaging such as non-MRI compatible implanted metallic devices including cardiac pacemakers, size limitations, etc.
  3. Laboratory biochemical evidence of abnormal bleeding and/or coagulopathy, including risk factors for intraoperative or postoperative bleeding ( count less than 100,000 per cubic millimeter or abnormal )
  4. Cerebrovascular disease (e.g. CVA within 6 months) or history of intracranial hemorrhage
  5. Untreated, uncontrolled sleep apnea
  6. Receiving anticoagulant (e.g. warfarin) or antiplatelet (e.g. aspirin) therapy within one week of focused ultrasound procedure or drugs known to increase risk or hemorrhage (e.g. Avastin) within one month of focused ultrasound procedure
  7. Individuals who are not able or willing to tolerate the required prolonged stationary supine position during treatment
  8. Are participating or have participated in another clinical trial in the last 30 days
  9. Patients unable to communicate with the investigator and staff.
  10. Presence of significant cognitive impairment
  11. History of psychosis on clinical evaluation.
  12. Patients with brain tumors already known or revealed on pretreatment MRI
  13. Currently pregnant (as determined by history and serum HCG) or lactating.
  14. Chemical abuse or dependence within the previous six months
  15. Presence of a metabolic pathology interfering with eating or digestion (e.g. diabetes).
  16. (BMI) less than 13
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
10 participants (estimated)

Study arms

  • Experimental
    MR- guided Focused Ultrasound Capsulotomy

    Participants in this arm will undergo a single MRI-guided focused ultrasound (MRgFUS) thermal ablation procedure targeting the anterior limb of the internal capsule (ALIC). The procedure is performed using the ExAblate 4000 MRgFUS system, with real-time MR thermometry to ensure precise lesioning. This intervention is intended for individuals with treatment-refractory anorexia nervosa (AN) and comorbid obsessive-compulsive disorder (OCD) and/or major depressive disorder (MDD) who meet surgical eligibility criteria. All participants will complete standardized psychiatric and quality of life assessments at baseline and follow-up time points up to 24 months post-treatment to evaluate safety, feasibility, and preliminary clinical efficacy.

    Device: ExAblate Neuro 4000

Interventions

  • DeviceExAblate Neuro 4000

    The ExAblate Neuro 4000 is an MRI-guided focused ultrasound (MRgFUS) system designed to perform noninvasive thermal ablation of targeted brain tissue. In this study, the ExAblate Neuro 4000 will be used to perform a bilateral capsulotomy by ablating the anterior limb of the internal capsule (ALIC) in patients with treatment-refractory anorexia nervosa (AN) and comorbid obsessive-compulsive disorder (OCD) and/or major depressive disorder (MDD). The procedure will be conducted under real-time MRI guidance and thermometry to ensure accurate targeting and controlled thermal delivery. This study aims to evaluate the safety, feasibility, and preliminary clinical benefit of MRgFUS in improving psychiatric symptoms and quality of life in this patient population.

06

What researchers measure

Primary outcomes

  1. Safety and Feasibility of MRgFUS Capsulotomy in Patients with Treatment-Refractory Anorexia Nervosa

    The frequency and severity of adverse events associated with ExAblate Transcranial Magnetic Resonance-guided Focused Ultrasound (MRgFUS) will be evaluated in patients with treatment-refractory anorexia nervosa and comorbid obsessive-compulsive disorder (OCD) and/or major depressive disorder (MDD). All adverse events-including procedure-related complications, neurological events, and other safety concerns-will be systematically documented, monitored, and assessed throughout the study duration.

    Time frame: From day of treatment through 24 months post-treatment with evaluations at immediate post-op, 1, 3, 6, 12, 18 and 24 months.

Secondary outcomes

  1. Change in Body Mass Index Following MRgFUS Capsulotomy

    Body Mass Index (BMI) will be used as an objective indicator of weight change and nutritional status. BMI will be calculated using weight (kg) divided by height (m²). Participants' BMI will be tracked over time to evaluate whether MRgFUS targeting the anterior limb of the internal capsule (ALIC) is associated with weight stabilization or improvement in individuals with treatment-refractory anorexia nervosa. Recommended BMI (Body Mass Index) for most adults is generally: Underweight: Below 18.5 Normal/Healthy weight: 18.5 - 24.9 Overweight: 25.0 - 29.9 Obese: 30.0 and above Notes: 1. The above mentioned ranges are from the World Health Organization (WHO) and are intended for adults 18-65 years old. 2. BMI is a quick screening tool but doesn't account for muscle mass, bone density, age or gender.

    Time frame: Assessments will be conducted at baseline, 1, 3, 6, 12, 18, and 24 months following the procedure.

  2. Change in Depressive Symptoms Using the Beck Depression Inventory

    The Beck Depression Inventory (BDI) is a 21-item self-report inventory assessing the presence and severity of depressive symptoms. Each item is scored from 0 to 3, with a total score range of 0 to 63. Higher scores reflect more severe depressive symptoms.

    Time frame: Baseline, 1 month, 3 months, 6 months, 12 months, 18 months, and 24 months post-treatment.

  3. Change in Anxiety Symptoms Using the Beck Anxiety Inventory

    Evaluate the effectiveness of MR-guided Focused Ultrasound (MRgFUS) in reducing anxiety symptom severity using the Beck Anxiety Inventory (BAI), a validated patient-reported scale. Assessments will occur at baseline and at specified follow-up visits. The BAI consists of 21 items measuring common symptoms of anxiety experienced over the past week. Each item is rated on a scale from 0 (not at all) to 3 (severely). Total scores range from 0 to 63, with higher scores indicating more severe anxiety symptoms

    Time frame: Baseline, 1 month, 3 months, 6 months, 12 months, 18 months, and 24 months post-treatment.

  4. Change in Quality of Life Using the Quality of Life Enjoyment and Satisfaction Questionnaire

    The Quality of Life Enjoyment and Satisfaction Questionnaire (QLESQ-SF) is a 14-item self-report questionnaire evaluating life satisfaction across various domains (e.g., physical health, mood, work, social life). Items are scored from 1 (very poor) to 5 (very good) and converted to a percentage (0-100%).

    Time frame: Baseline, 1 month, 3 months, 6 months, 12 months, 18 months, and 24 months post-treatment.

  5. Change in Obsessive-Compulsive Symptoms Using the Obsessive Compulsive Inventory

    Obsessive Compulsive Inventory (OCI) - The Obsessive Compulsive Inventory is a self-report questionnaire used to assess the severity of obsessive-compulsive symptoms across six domains: washing, checking, ordering, obsessing, hoarding, and mental neutralizing. It consists of items scored from 0 (not at all) to 4 (extremely), with total scores ranging from 0 (no symptoms) to 72 (most severe symptoms). Higher scores indicate a worse outcome (greater severity of obsessive-compulsive symptoms).

    Time frame: Baseline, 1 month, 3 months, 6 months, 12 months, 18 months, and 24 months post-treatment.

  6. Change in Suicide Risk Using the Columbia-Suicide Severity Rating Scale

    Columbia-Suicide Severity Rating Scale (C-SSRS) - The Columbia-Suicide Severity Rating Scale is a clinician-administered tool that evaluates suicidal ideation and behavior, including the severity and intensity of thoughts and the presence of actual, interrupted, or aborted suicide attempts. Scores range from 0 (no suicidal ideation or behavior) to 25 (most severe), with higher scores indicating a worse outcome (greater suicidal risk).

    Time frame: Baseline, 1 month, 3 months, 6 months, 12 months, 18 months, and 24 months post-treatment.

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it moved

Started Sep 2025 (actual). Primary completion is estimated for Aug 2028, 35 months after the start.

Start moved once since we started tracking on Sep 25, 2026: Aug 2025 → Sep 2025, on Nov 19, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Aug 6, 2025
First posted
Aug 11, 2025
StartActual
Sep 5, 2025was Aug 2025
Primary completionEst.
Aug 2028
CompletionEst.
Aug 2028
Last update
Nov 19, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Start date
Aug 2025→Sep 5, 2025 (actual)
Nov 19, 2026
Show all 1 update
  1. Nov 19, 2026
    Start date Aug 2025→Sep 5, 2025 (now actual)
    + 2 other changes: verification date and site details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07113665
Responsible party
Dr. Nir Lipsman (Principal Investigator, Sunnybrook Health Sciences Centre) — Principal investigator
First posted
Aug 11, 2025
Start date
Sep 5, 2025
Primary completion
Aug 2028 (estimated)
Completion
Aug 2028 (estimated)
Last update
Nov 19, 2026

Study contacts

Nir Lipsman, MD, PhD, FRCSC
Contact
Nir.Lipsman@sunnybrook.ca
416-480-6954
Anusha Baskaran, PhD
Contact
anusha.baskaran@sunnybrook.ca
416-480-6100 ext. 61650

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion